Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of disease-modifying therapies on pain, fatigue and QOL in NMOSD
jRCT1030210419Not yet recruiting
- Sponsor
- University of Tsukuba
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by University of Tsukuba. Primary endpoints: Motor function, Activities of daily living (ADL) and 5 more. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCT1030210419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030210419.